Summarized by Masters of Longevity from Peter Attia Blog.
Assessments of long‑standing symptomatic Alzheimer’s drugs review how much cognitive function cholinesterase inhibitors preserve and what trial measures show.
Key Takeaways
- Pooled trials show cholinesterase inhibitors improve ADAS‑Cog scores by about 2–3 points versus placebo after six months.
- Estimated minimum clinically important differences on ADAS‑Cog in mild Alzheimer’s typically sit around 3–4 points.
- The measured group advantage mainly reflects slower decline versus placebo rather than clear within‑patient improvement.
